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and anti-poliovirus drugs to reduce the risk of reintroduction VDPV
viruses from chronically infected immunodeﬁcient persons.
http://dx.doi.org/10.1016/j.ijid.2014.03.550
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Novel vaccine strategies to control inﬂuenza
infections
K. Neuzil
PATH, Seattle, USA
The global burden of inﬂuenza is substantial. Ample data from
high resource settings supports that inﬂuenza infection leads
to hospitalizations, deaths, excess medication usage, and days
missed from work and school on an annual basis. Likewise, there
is an increasing recognition of the high inﬂuenza burden in low
resource countries, although most of our knowledge is limited to
the direct effects of inﬂuenza illness and less is known about the
indirect effects on school or work productivity or the ﬁnancial
consequences.
Inﬂuenza is a preventable disease, and advisory bodies
throughout the world, including the World Health Organization,
recommend inﬂuenza vaccine for various age groups and risk
groups within the population. In 2013, an unprecedented num-
ber of inﬂuenza vaccines are available on the worldwide market,
including quadrivalent vaccines, live-attenuated vaccines, high
dose vaccines, vaccines administered intradermally and vaccines
manufactured in cell culture. Many more inﬂuenza vaccines are in
development, and it is anticipated that the diversity of inﬂuenza
vaccine choices will continue to increase. Comparative trials are
beginning to elucidate the relative beneﬁts of certain vaccines in
particular age groups and populations.
This talk will focus on the deployment of particular vaccines
and novel strategies to improve inﬂuenza prevention programs.
The relative advantages anddisadvantagesofdifferent vaccines and
vaccination strategies will be discussed, with a look into the future
of inﬂuenza vaccine control in various settings.
http://dx.doi.org/10.1016/j.ijid.2014.03.551
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New trends in the treatment of infectious
diseases caused by antibiotic resistant bacteria
Y. Ishii
Toho University School of Medicine, Tokyo, Japan
Multidrug resistant (MDR) bacteria are a major concern in the
worldwide. There remain some useful antibiotics for infectious dis-
eases caused by MDR Gram-positive organisms. On the other hand,
treatment of infections caused by MDR Gram-negative bacteria
is quite a predicament because the number of effective antibi-
otics is limited. One of the options is colistin. A lot of articles
have reported neurotoxicity or nephrotoxicity with colistin. The
injectable colistin does not show enough efﬁciency for treating
pneumonia, because this drug attains low concentrations in the
lung. Furthermore, some organisms, including Proteae and Serratia
spp., show natural resistance for colistin. Colistin is not com-
mercially available in Japan. Another option is tigecycline. This
compound shows antibiotic activity against both Gram-negative
organisms and Gram-positive organisms. Unfortunately, this drug
does not show antibiotic activity against Pseudomonas aeruginosa.
More therapeutic options are needed. We ﬁrst constructed a tool
for ﬁnding combination antibiotics by the modiﬁed checker board
method. In Japan, the combination of amikacin and aztreonam
is most effective combination for MDR P. aeruginosa including
metallo-beta-lactamase (MBL)producers.Anotheruseful option for
MBL producing organisms is the combination of Braian® (EDTA-
calcium) and beta-lactams, such as imipenem or ceftazidime. The
effectivenessof this combinationhasbeenconﬁrmedby invitroand
invivo experimentsusing themurine experimentalmodel. Another
problem for infectious diseases by Gram-negative organism is
endotoxin shock. Polymixycins can capture the lipopolysaccha-
rides of Gram-negative bacteria. We have evaluated continuously
infused lowdoes colistin usingmicrosphere in themurine infection
model.Ourdata suggests that colistin canprotect against endotoxin
shock. In thispresentation,wediscuss thesenovel treatment strate-
gies against infectious diseases caused by MDR Gram-negative
organisms.
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